HWAM
VRDN icon

Hennion & Walsh Asset Management’s Viridian Therapeutics VRDN Stock Holding History

Hennion & Walsh Asset Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.84M Buy
209,092
+34,198
+20% +$551K 0.11% 238
2026
Q1 		$3.42M Buy
174,894
+5,727
+3% +$170K 0.12% 227
2025
Q4 		$5.26M Buy
169,167
+14,829
+10% +$407K 0.18% 134
2025
Q3 		$3.33M Sell
154,338
-13,986
-8% -$252K 0.12% 222
2025
Q2 		$2.35M Sell
168,324
-30,869
-15% -$419K 0.1% 276
2025
Q1 		$2.69M Sell
199,193
-11,706
-6% -$199K 0.12% 212
2024
Q4 		$4.04M Buy
210,899
+13,498
+7% +$293K 0.18% 134
2024
Q3 		$4.49M Buy
197,401
+18,546
+10% +$303K 0.21% 111
2024
Q2 		$2.33M Buy
178,855
+69,035
+63% +$956K 0.12% 226
2024
Q1 		$1.92M Buy
109,820
+34,040
+45% +$660K 0.1% 264
2023
Q4 		$1.65M Buy
75,780
+48,668
+180% +$768K 0.09% 283
2023
Q3 		$416K Buy
27,112
+12,807
+90% +$244K 0.03% 571
2023
Q2 		$340K Buy
+14,305
New +$367K 0.02% 615

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Hennion & Walsh Asset Management's VRDN Position: Q2 2026 in Review

Hennion & Walsh Asset Management increased its Viridian Therapeutics (VRDN) stake by 20% in Q2 2026, buying an estimated $551K and bringing the position to 209,092 shares worth $3.84M. The position accounts for 0.11% of the portfolio, ranked #238.

Hennion & Walsh Asset Management first reported a position in VRDN in Q2 2023 and has held it in 13 quarters since. The position peaked at $5.26M in Q4 2025. 212 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Hennion & Walsh Asset Management held 209,092 shares of Viridian Therapeutics worth $3.84M as of Q2 2026.
  • Hennion & Walsh Asset Management bought 34,198 Viridian Therapeutics shares in Q2 2026, an estimated $551K.
  • Viridian Therapeutics made up 0.11% of Hennion & Walsh Asset Management's portfolio in Q2 2026, its #238 holding.
  • Hennion & Walsh Asset Management first reported a position in Viridian Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • Hennion & Walsh Asset Management's Viridian Therapeutics position peaked at $5.26M in Q4 2025.
  • 212 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Hennion & Walsh Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.